Consistent with previous results, patients with high expression of PTGIS had a poor prognosis in both lung cancer (OS HR=1.47, 95% CI=1.28 to 1.69, P=4.8e-08; PFS HR=2.13, 95% CI=1.74 to 2.6, P=3.5e-14) and ovarian cancer (OS HR=1.23, 95% CI=1.08 to 1.4, P=0.002; PFS HR=1.26, 95% CI=1.11 to 1.43, P=3.1e-4) (Figure 3E–3H). This evidence concerns the gene PTGIS and ovarian carcinoma.